RT Journal Article
T1 Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report
A1 Andrade-Bellido, Raúl Jesús
A1 Aithal, Guruprasad P.
A1 De Boer, Ynto S.
A1 Liberal, Rodrigo
A1 Gerbes, Alexander L
A1 Regev, Arie
A1 Terziroli Beretta-Piccoli, Benedetta
A1 Schramm, Christoph
A1 Kleiner, David E.
A1 De Martin, Eleonora
A1 Kullak-Ublick, Gerd A
A1 Stirnimann, Guido
A1 Devarbhavi, Harshad
A1 Vierling, John M.
A1 Manns, Michael P.
A1 Sebode, Marcial
A1 Londoño, María Carlota
A1 Avigan, Mark
A1 Robles-Díaz, María Mercedes
A1 García-Cortés, Miren
A1 Atallah, Edmond
A1 Heneghan, Michael
A1 Chalasani, Naga
A1 Trivedi, Palak J.
A1 Hayashi, Paul H.
A1 Taubert, Richard
A1 Fontana, Robert J.
A1 Weber, Sabine
A1 Oo, Ye Htun
A1 Zen, Yoh
A1 Licata, Anna
A1 Lucena-González, María Isabel
A1 Mieli-Vergani, Giorgina
A1 Vergani, Diego
A1 Bjornsson, Einar S.
K1 Hígado - Enfermedades
K1 Hígado - Efectos de los medicamentos
AB Drug-induced liver injury (DILI) can mimic almost all other liver disorders. A phenotype increasingly ascribed to drugs is autoimmune-like hepatitis (ALH). This article summarises the major topics discussed at a joint International Conference held between the Drug-Induced Liver Injury consortium and the International Autoimmune Hepatitis Group. DI-ALH is a liver injury with laboratory and/or histological features that may be indistinguishable from those of autoimmune hepatitis (AIH). Previous studies have revealed that patients with DI-ALH and those with idiopathic AIH have very similar clinical, biochemical, immunological and histological features. Differentiating DI-ALH from AIH is important as patients with DI-ALH rarely require long-term immunosuppression and the condition often resolves spontaneously after withdrawal of the implicated drug, whereas patients with AIH mostly require long-term immunosuppression. Therefore, revision of the diagnosis on long-term follow-up may be necessary in some cases. More than 40 different drugs including nitrofurantoin, methyldopa, hydralazine, minocycline, infliximab, herbal and dietary supplements (such as Khat and Tinospora cordifolia) have been implicated in DI-ALH. Understanding of DI-ALH is limited by the lack of specific markers of the disease that could allow for a precise diagnosis, while there is similarly no single feature which is diagnostic of AIH. We propose a management algorithm for patients with liver injury and an autoimmune phenotype. There is an urgent need to prospectively evaluate patients with DI-ALH systematically to enable definitive characterisation of this condition.
PB Elsevier
YR 2023
FD 2023
LK https://hdl.handle.net/10630/27267
UL https://hdl.handle.net/10630/27267
LA eng
NO Raúl J. Andrade, Guruprasad P. Aithal, Ynto S. de Boer, Rodrigo Liberal, Alexander Gerbes, Arie Regev, Benedetta Terziroli Beretta-Piccoli, Christoph Schramm, David E. Kleiner, Eleonora De Martin, Gerd A. Kullak-Ublick, Guido Stirnimann, Harshad Devarbhavi, John M. Vierling, Michael P. Manns, Marcial Sebode, Maria Carlota Londoño, Mark Avigan, Mercedes Robles-Diaz, Miren García-Cortes, Edmond Atallah, Michael Heneghan, Naga Chalasani, Palak J. Trivedi, Paul H. Hayashi, Richard Taubert, Robert J. Fontana, Sabine Weber, Ye Htun Oo, Yoh Zen, Anna Licata, M Isabel Lucena, Giorgina Mieli-Vergani, Diego Vergani, Einar S. Björnsson, Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report, Journal of Hepatology, 2023,  1-14
NO Funding for open access charge: Universidad de Málaga/CBUA
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 20 ene 2026